share_log

HC Wainwright & Co. Maintains Buy on Sana Biotechnology, Lowers Price Target to $11

HC Wainwright & Co. Maintains Buy on Sana Biotechnology, Lowers Price Target to $11

HC Wainwright & Co.維持對Sana生物技術的買入評級,將目標價調降至11美元。
Benzinga ·  08/10 04:53  · 評級/大行評級

HC Wainwright & Co. analyst Emily Bodnar maintains Sana Biotechnology (NASDAQ:SANA) with a Buy and lowers the price target from $12 to $11.

HC Wainwright & Co.分析師Emily Bodnar維持對Sana Biotechnology (NASDAQ:SANA)的買入評級,並將目標股價從12美元下調至11美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論